Melissa Huynh
Has grant
Assistant Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Melissa Huynh is an Assistant Professor at Western University, Canada. Her research focuses on the management and treatment of genitourinary cancers, particularly in relation to renal cell carcinoma and prostate cancer. Recent articles include studies on radioembolization therapy, lymph node dissection complications, and therapeutic monitoring guidelines. She is actively involved in advancing knowledge in cancer management through both clinical trials and population-based assessments.
Recent Grants
Grant: Close
Exploring the role of Akkermansia muciniphilia in combating the metabolic effects of androgen deprivation therapy in men with metastatic prostate cancer
Open Date: 2022-12-01
Close Date:
Grant: Close
Exploring the role of intravesical hydrogen sulfide synthesis inhibitors in a murine model of urothelial carcinoma of the bladder
Open Date: 2022-06-01
Close Date: 2023-06-01
Grant: Close
Detection of metastatic clear cell renal cell carcinoma with [18F]-PSMA-1007 PET imaging compared to conventional CT imaging
Open Date: 2021-12-01
Close Date: 2022-11-01
Grant: Close
Exploring the role of Akkermansia muciniphilia in combating the metabolic effects of androgen deprivation therapy in men with metastatic prostate cancer
Open Date:
Close Date:
Grant: Close
Yittrium-90 Radioembolization for Management of Non-Metastatic Renal Cell Carcinoma
Open Date:
Close Date:
Articles (16)
Year:
2026
Year:
2025
Introduction: Retroperitoneal lymph node dissection (RPLND) is a procedure of significant therapeutic and diagnostic value in the management of testicular cancer. This study aimed to conduct a contemporary review of surgical outcomes following RPLND procedures performed in North America over the last decade. Methods: We queried the National Surgical Quality Improvement Program (NSQIP) database from 20122022 (n=9 857 040) to identify patients who underwent RPLND and were diagnosed with testicular cancer. The primary outcome was 30-day morbidity. Secondary outcomes included time-to-complication analysis, rate of additional organ resection, hospital length of stay (LOS), and readmission rates. Binomial logistic regression and a generalized linear model were used to identify risk factors associated with 30-day morbidity and LOS. Results: A total of 513 RPLND procedures met the inclusion criteria. The median age was 30 years (interquartile range [IQR] 2436.50) with a body mass index of 27.9 kg/m2 (IQR 24.5– 32.0). There were no deaths within 30 days. The overall 30-day morbidity rate was 17% (n=86). Bleeding/transfusion postoperatively (12%), return to the operating room (3%), and superficial surgical site infection (2%) were the three most common complications. Factors associated with increased 30-day morbidity included: history of smoking (odds ratio [OR] 2.5, 95% confidence interval [CI] 1.35–4.68) and concurrent vascular repair/reconstruction (OR 4.1, 95% CI 1.12–15.46). The median LOS was four days (IQR 3–6) and the 30-day readmission rate was 7.0%. Conclusions: This study underscores that approximately one in six patients experience complications following RPLND in North America. Identifying the timing of and risk factors for these complications can improve physician-patient communication and overall care.
Year:
2025
Background Mucosa-associated invariant T (MAIT) cells represent a unique population of innate-like T lymphocytes capable of detecting non-peptide antigens in the context of monomorphic antigen-presenting molecules. Due to their abundance in barrier tissues, reactivity to local inflammatory cues, and cytotoxic and regulatory functions, MAIT cells are poised to shape the dynamics of various tumor microenvironments. Growing evidence suggests that MAIT cells can exert protumor and/or antitumor effects in cancers arising from or metastasizing to mucosal tissues. However, MAIT cell roles in bladder cancer (BCa) remains unclear. Methods To begin to identify MAIT cells in BCa, we stained bladder tumor biopsies for T cell receptor (TCR) Vα7.2 + cells. We then refined a human MAIT cell signature, which enabled us to interrogate a bulk RNA sequencing dataset and conduct correlation analyses linking intratumoral MAIT cell abundance and mortality from BCa. To extend our work to an in vivo setting, we employed a clinically relevant mouse model in which Mr1 +/+ B6-MAIT CAST (MAIT-sufficient) and Mr1 −/− B6-MAIT CAST (MAIT-deficient) mice were exposed to N-butyl-N-(4-hydroxybutyl)nitrosamine, a chemical carcinogen associated with tobacco smoke. In additional experiments, MAIT cells were functionally removed through acetyl-6-formylpterin (Ac-6-FP) administration. Effector and regulatory cell types were phenotyped by flow cytometry, and BCa tumor burden and progression were assessed by MRI and/or H&E and Ki67 staining. Results TCR Vα7.2 + cells were readily detectable in several BCa biopsies, and our bioinformatic analyses correlated heavier MAIT cell presence in BCa tumors with poorer overall survival. Similarly, we found higher tumor burdens in Mr1 +/+ B6-MAIT CAST mice than in Mr1 −/− or Ac-6-FP-treated animals. Bladder MAIT cells from tumor-bearing mice exhibited phenotypic MAIT17 bias based on transcription factors they harbored along with increased interleukin-17A and tumor necrosis factor-α production capacities upon stimulation. Finally, FoxP3 + regulatory T (T reg ) cell frequencies were elevated in Mr1 +/+ mouse bladder tumors, likely contributing to an immunosuppressive tumor microenvironment, a finding that could be recapitulated in our transcriptomic studies on human BCa. Conclusions MAIT cells are abundant in BCa tumor microenvironments where they potentiate T reg cell accumulation and play protumor roles.
Year:
2025
Small-cell carcinomas (SCCs) of the genitourinary (GU) tract are rare malignancies with high metastatic potential. The most common primary sites are the bladder and prostate, but case reports of primary SCC of the kidney, ureter, and urethra also exist. The majority of patients present with gross hematuria, irritative or obstructive urinary symptoms, and symptoms of locoregionally advanced or metastatic disease at initial presentation. SCC of the bladder presents with nodal or metastatic involvement in the majority of cases and requires the use of platinum-based chemotherapy in combination with surgery and/or radiation. SCC of the prostate is most commonly seen in the metastatic castrate-resistant setting, and aggressive variant disease presents with a greater propensity for visceral metastases, osteolytic lesions, and relatively low serum prostate-specific antigen for volume of disease burden. Multiple retrospective and prospective randomized studies support the use of a multimodal approach combining platinum-based systemic therapy regimens with radiation and/or surgery for localized disease. This evidence-based strategy is reflected in multiple consensus guidelines. Emerging data suggest that small-cell bladder and prostate cancers transdifferentiate from a common progenitor of conventional urothelial bladder carcinoma and prostatic acinar adenocarcinoma, respectively. Areas of active basic research include efforts to identify the key genetic and epigenetic drivers involved in the emergence of small cell cancers to exploit them for novel therapies. Here, we review these efforts, discuss diagnosis and currently supported management strategies, and summarize ongoing clinical trials evaluating novel therapies to treat this rare, aggressive GU cancer.
Year:
2024
Present bladder cancer therapies have relatively limited therapeutic impact and account for one of the highest lifetime treatment costs per patient. Therefore, there is an urgent need to explore novel and optimized treatment strategies. The present study investigated the effects of inhibiting endogenous hydrogen sulfide (H2S) production on bladder cell viability and in vivo tumor progression. We targeted the H2S-producing enzyme, cystathionine γ-lyase, in 5637 cells using propargylglycine (H2S inhibitor) and performed cytofluorimetric analysis to evaluate cell viability. We then tested the efficacy of propargylglycine alone or in combination with gemcitabine (conventional chemotherapy) in an intravesical murine model of bladder cancer. Magnetic resonance imaging and immunohistochemical staining for cell proliferation, apoptosis, immune-cell infiltration, and neovascularization were performed to evaluate tumor response. Compared to control conditions or cohorts, propargylglycine administration significantly attenuated bladder cancer cell viability in vitro (p < 0.0001) and tumor growth (p < 0.002) and invasion in vivo. Furthermore, propargylglycine enhanced the anti-cancer effects of gemcitabine, resulting in tumor regression (p < 0.0001). Moreover, propargylglycine induced cleaved PARP-1-activated apoptosis (p < 0.05), as well as intratumoral CD8+ T cell (p < 0.05) and F4/80+ macrophage (p < 0.002) infiltration. Propargylglycine also reduced intratumoral neovascularization (p < 0.0001) and cell proliferation (p < 0.0002). Importantly, the pro-apoptotic and anti-neovascularization effects of gemcitabine were enhanced by propargylglycine co-administration. Our findings suggest that inhibition of endogenous H2S production can be protective against bladder cancer by enhancing the chemotherapeutic action of gemcitabine and may be a novel pharmacological target and approach for improved bladder cancer diagnosis and treatments in the future.
Year:
2024
Year:
2024
Background Androgen‐deprivation therapy (ADT) remains a cornerstone in treatment for patients with advanced prostate cancer. ADT is associated with several adverse effects, including osteoporosis, metabolic syndrome, and cardiovascular events, leading to guidelines recommending routine testing to monitor for these toxicities. There is a lack of data assessing adherence to these recommendations. Methods The authors conducted a retrospective cohort study using administrative data from Ontario, Canada between 2008 and 2021. They identified all older men (aged 65 years and older) who received ADT for prostate cancer using comprehensive provincial health databases. The primary outcomes were the use of testing for lipids, dysglycemia (glucose), bone health serum, and bone density between 6 weeks before and 1 year after the initiation of ADT. Results In total, 29,097 patients were examined, of whom 52.8% were prescribed ADT by urologists, 37.9% were prescribed ADT by radiation oncologists, 2.8% were prescribed ADT by medical oncologists, and 2.4% were prescribed ADT by other physicians. Adherence to guidelines was low: only 21.3% of patients received a bone density scan, 41.2% underwent bone health–related serum tests, 51.3% completed a lipid profile, and 65.9% underwent dysglycemia testing within 1 year of diagnosis. Overall, only 11.9% of patients received all of the recommended investigations. Adherence to testing did not appear to improve over time (2008–2021) or with guideline publication. Patient (age) and physician (specialty) factors had important associations with adherence to testing. Conclusions Most patients receiving ADT for prostate cancer do not receive recommended testing to monitor for treatment‐related toxicity. Further study is required to address barriers to therapeutic monitoring of men on ADT and to reduce treatment‐associated adverse events.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2021
Year:
2021
Year:
2020
Year:
2020
Collaborators (5)
S M Mansour Haeryfar
Professor
Western University
Leandro Cardarelli Leite
Assistant Professor
Western University
Omar Mian
Associate Professor
Fred Hutch Cancer Center
Brant Inman
Chin-Hardie Chair of Urologic Oncology
Western University
Timothy Scholl
Investigator
Western University
Make your next move.
Prepare your application
Review drafts before you send them.